Despite the growing body of knowledge on the role of DLL3 in lung cancer, there remains a significant gap in our understanding of the actual expression rate of DLL3 when assessed by immunohistochemistry (IHC) in routine clinical laboratories. The gene discussed is DLL3; the disease is lung cancer.